skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 19,599  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Covid-19 vaccine immunogenicity in people living with HIV-1
Covid-19 vaccine immunogenicity in people living with HIV-1
Material Type:
Article 		Add to My Research

Covid-19 vaccine immunogenicity in people living with HIV-1

Vaccine, 2022-06, Vol.40 (26), p.3633-3637 [Peer Reviewed Journal]

2022 The Authors ;Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. ;2022. The Authors ;2022 The Authors 2022 ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2022.04.090 ;PMID: 35568588

Full text available

Citations Cited by
2
Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes
Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes
Material Type:
Article 		Add to My Research

Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes

Frontiers in immunology, 2016-02, Vol.7, p.21-21 [Peer Reviewed Journal]

COPYRIGHT 2016 Frontiers Research Foundation ;Copyright © 2016 Krishna and Nadler. 2016 Krishna and Nadler ;ISSN: 1664-3224 ;EISSN: 1664-3224 ;DOI: 10.3389/fimmu.2016.00021 ;PMID: 26870037

Full text available

Citations Cited by
3
Publisher Correction: A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines
Publisher Correction: A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines
Material Type:
Article 		Add to My Research

Publisher Correction: A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines

Scientific reports, 2019-10, Vol.9 (1), p.1-1, Article 14730 [Peer Reviewed Journal]

2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2019 ;ISSN: 2045-2322 ;EISSN: 2045-2322 ;DOI: 10.1038/s41598-019-50828-3 ;PMID: 31594990

Full text available

Citations Cited by
4
High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases
High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases
Material Type:
Article 		Add to My Research

High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases

Annals of the rheumatic diseases, 2021-10, Vol.80 (10), p.1351-1352 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. https://bmj.com/coronavirus/usage? ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2021-220656 ;PMID: 34031032

Full text available

Citations Cited by
5
Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection:an overview of systematic reviews
Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection:an overview of systematic reviews
Material Type:
Article 		Add to My Research

Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection:an overview of systematic reviews

ISSN: 1471-2334 ;EISSN: 1471-2334 ;DOI: 10.1186/s12879-023-08541-0

Full text available

Citations Cited by
6
Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection:an overview of systematic reviews
Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection:an overview of systematic reviews
Material Type:
Article 		Add to My Research

Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection:an overview of systematic reviews

ISSN: 1471-2334 ;EISSN: 1471-2334 ;DOI: 10.1186/s12879-023-08541-0

Full text available

Citations Cited by
7
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting
Material Type:
Article 		Add to My Research

SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting

Gut, 2021-04, Vol.70 (4), p.635-640 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021 ;ISSN: 0017-5749 ;ISSN: 1468-3288 ;EISSN: 1468-3288 ;DOI: 10.1136/gutjnl-2020-324000 ;PMID: 33472895

Full text available

Citations Cited by
8
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Material Type:
Article 		Add to My Research

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

Nature reviews. Clinical oncology, 2022-06, Vol.19 (6), p.385-401 [Peer Reviewed Journal]

2022. Springer Nature Limited. ;Springer Nature Limited 2022. ;Springer Nature Limited 2022 ;ISSN: 1759-4774 ;EISSN: 1759-4782 ;DOI: 10.1038/s41571-022-00610-8 ;PMID: 35277694

Full text available

Citations Cited by
9
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
Material Type:
Article 		Add to My Research

What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2

The Lancet Infectious Diseases, 2021-02, Vol.21 (2), p.e26-e35 [Peer Reviewed Journal]

2021 Elsevier Ltd ;Copyright © 2021 Elsevier Ltd. All rights reserved. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.elsevier.com/legal/elsevier-website-terms-and-conditions ;2021. Elsevier Ltd ;2020 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd ;ISSN: 1473-3099 ;EISSN: 1474-4457 ;DOI: 10.1016/S1473-3099(20)30773-8 ;PMID: 33125914

Digital Resources/Online E-Resources

Citations Cited by
10
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
Material Type:
Article 		Add to My Research

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

New England Journal of Medicine, 2021-05, Vol.384 (19), p.1824-1835 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2034201 ;PMID: 33440088

Digital Resources/Online E-Resources

Citations Cited by
11
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
Material Type:
Article 		Add to My Research

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

New England Journal of Medicine, 2021-09, Vol.385 (13), p.1172-1183 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2107659 ;PMID: 34192426

Digital Resources/Online E-Resources

Citations Cited by
12
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Material Type:
Article 		Add to My Research

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

New England Journal of Medicine, 2020-12, Vol.383 (24), p.2320-2332 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;COPYRIGHT 2020 Massachusetts Medical Society ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2020 Massachusetts Medical Society. All rights reserved. 2020 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2026920 ;PMID: 32877576

Digital Resources/Online E-Resources

Citations Cited by
13
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
Material Type:
Article 		Add to My Research

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

The Lancet (British edition), 2021-12, Vol.398 (10318), p.2258-2276 [Peer Reviewed Journal]

2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. ;Copyright © 2021 The Author(s). Published by Elsevier Ltd. Published by Elsevier Ltd.. All rights reserved. ;2021. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 The Author(s). Published by Elsevier Ltd. 2021 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)02717-3 ;PMID: 34863358

Full text available

Citations Cited by
14
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
Material Type:
Article 		Add to My Research

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

New England Journal of Medicine, 2021-12, Vol.385 (25), p.2348-2360 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2105290 ;PMID: 34587382

Digital Resources/Online E-Resources

Citations Cited by
15
Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort study
Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort study
Material Type:
Article 		Add to My Research

Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort study

Vaccine, 2024-02, Vol.42 (5), p.1145-1153 [Peer Reviewed Journal]

2024 The Authors ;Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. ;2024. The Authors ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2024.01.047 ;PMID: 38262809

Full text available

Citations Cited by
16
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
Material Type:
Article 		Add to My Research

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

The lancet oncology, 2021-06, Vol.22 (6), p.765-778 [Peer Reviewed Journal]

2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2021. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2021 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00213-8 ;PMID: 33930323

Full text available

Citations Cited by
17
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
Material Type:
Article 		Add to My Research

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

The Lancet (British edition), 2021-09, Vol.398 (10303), p.856-869 [Peer Reviewed Journal]

2021 ;Crown Copyright © 2021 Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. ;Copyright Elsevier Limited Sep 4, 2021 ;Crown Copyright © 2021 Published by Elsevier Ltd. 2021 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)01694-9 ;PMID: 34370971

Full text available

Citations Cited by
18
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
Material Type:
Article 		Add to My Research

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

The Lancet infectious diseases, 2022-04, Vol.22 (4), p.483-495 [Peer Reviewed Journal]

2022 Elsevier Ltd ;Copyright © 2022 Elsevier Ltd. All rights reserved. ;2022. Elsevier Ltd ;2021 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd ;ISSN: 1473-3099 ;EISSN: 1474-4457 ;DOI: 10.1016/S1473-3099(21)00681-2 ;PMID: 34890537

Full text available

Citations Cited by
19
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Material Type:
Article 		Add to My Research

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

The Lancet infectious diseases, 2021-06, Vol.21 (6), p.803-812 [Peer Reviewed Journal]

2021 Elsevier Ltd ;Copyright © 2021 Elsevier Ltd. All rights reserved. ;2021. Elsevier Ltd ;2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd ;ISSN: 1473-3099 ;EISSN: 1474-4457 ;DOI: 10.1016/S1473-3099(20)30987-7 ;PMID: 33548194

Full text available

Citations Cited by
20
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial
Material Type:
Article 		Add to My Research

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial

The Lancet infectious diseases, 2022-12, Vol.22 (12), p.1728-1736 [Peer Reviewed Journal]

2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license ;Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2022. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. This work is published under http://creativecommons.org/licenses/by-nc-nd/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1473-3099 ;EISSN: 1474-4457 ;DOI: 10.1016/S1473-3099(22)00442-X ;PMID: 36087586

Full text available

Citations Cited by

Results 1 - 20 of 19,599  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (18,467)

Refine My Results

Creation Date 

From To
Refine
  1. Before 1981  (32)
  2. 1981 To 1991  (316)
  3. 1992 To 2002  (762)
  4. 2003 To 2014  (3,626)
  5. After 2014  (14,867)
  6. More options open sub menu

Subject 

  1. Immunogenicity  (18,046)
  2. Science & Technology  (16,763)
  3. Life Sciences & Biomedicine  (14,177)
  4. Vaccines  (8,752)
  5. Humans  (8,576)
  6. Immunology  (7,079)
  7. Animals  (6,062)
  8. Proteins  (5,596)
  9. Antigens  (5,577)
  10. Immune Response  (5,100)
  11. Antibodies  (4,985)
  12. Female  (4,271)
  13. Research & Experimental Medicine  (4,027)
  14. Medicine, Research & Experimental  (4,026)
  15. Vaccination  (4,018)
  16. Immunization  (3,942)
  17. Lymphocytes T  (3,747)
  18. Mice  (3,587)
  19. Viruses  (3,174)
  20. Infections  (3,108)
  21. More options open sub menu

Language 

  1. English  (19,463)
  2. Japanese  (1,862)
  3. Russian  (113)
  4. Portuguese  (69)
  5. Spanish  (33)
  6. Korean  (32)
  7. Norwegian  (27)
  8. Chinese  (26)
  9. French  (22)
  10. German  (21)
  11. Serbian  (3)
  12. Persian  (3)
  13. Slovak  (2)
  14. Czech  (2)
  15. Polish  (2)
  16. Italian  (2)
  17. Romanian  (2)
  18. Arabic  (1)
  19. Croatian  (1)
  20. Swedish  (1)
  21. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait